Global Anti-Infectives Market
Infectious diseases are one of the leading causes of morbidity and mortality throughout the world. The global market for all infectious diseases is expected to be ~$100 billion dollars by 2022, and is …
MABT’s current mission is to develop therapies for Rabies and advanced Flu patients.
IMT504 is a novel, patented immunotherapy that has shown robust results in testing
Our approach to combating bacteria and viruses can revolutionize medical care
Rabies is the world’s most lethal disease, killing virtually 100% of brain-infected patients
The Flu kills tens of thousands every year, new therapies for advanced Flu are essential
IMT504 is a novel oligodeoxynucleotide immunotherapy that has shown robust results in numerous animal safety and efficacy models, as well as in humans. Recent data suggest that IMT504 will be a highly effective therapy for advanced Coronavirus and flu patients. Additional exciting data suggests that the IMT504 platform could be an effective treatment for other diseases too.
IMT504 is our proprietary, patented technology platform with over $23 Million invested in research. Our technology platform creates a very rapid, safe and effective immune system response. IMT504 has the ability to address emergency situations like the current COVID-19 pandemic.
Infectious diseases are one of the leading causes of morbidity and mortality throughout the world. The global market for all infectious diseases is expected to be ~$100 billion dollars by 2022, and is …
Rabies represents a unique unmet medical need, for which there is no effective therapy. Rabies is the most lethal organism known to the medical community, with a fatality rate of …
Outside the US, over 700,000 deaths are currently attributed to resistant bacteria. However, given recent trends in resistance, these numbers are expected to skyrocket to over 10,000,000 deaths/year by 2050, …
We are always interested in hearing from you! Please fill out a contact us form and hit send. We will reply as soon as possible.
Thank you.